New FDA approval boosts survival in advanced pancreatic cancer; research reshapes therapy with earlier detection and personalized care.
Recent reporting shows targeted drugs, immunotherapies and refined radiochemotherapy are prolonging life for cancer patients. Trials indicate higher survival in younger groups and expanding use of genomic profiling. New therapies are pairing with existing treatments to push back relapse and increase quality of life, though access and long-term outcomes vary.
The FDA has approved daraxonrasib, sold as Rasonque, for patients with metastatic pancreatic cancer whose disease has progressed after chemotherapy. A 500‑patient trial has shown median overall survival of 13.2 months on the drug versus 6.7 months on chemotherapy. The oral pill targets multiple KRAS mutations and will be marketed by Revolution Medicines.